NCT04609579: Study of SNX281 in Subjects With Advanced Solid Tumors and Lymphoma

Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Therapeutic Antibody, Immunotherapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Breast cancer patients are only eligible for the dose escalation phase of the study
Exclusions: Patients with unstable, symptomatic, uncontrolled brain metastases- see trial for details; Patients with leptomeningeal disease; Patients with prior systemic stimulator of interferon genes (STING) agonist at any time (prior intra-tumoral STING agonist is acceptable)

Comments are closed.

Up ↑